Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

What happened: Hanmi Pharmaceutical's Eppe, Korea's first homegrown GLP-1 obesity drug, awaits Ministry of Food and Drug Safety approval and is expected to launch before year-end, with industry estimates of about 150,000 won for a four-week Why it matters: A lower price could pressure Wegovy and Mounjaro pricing, echoing Novo Nordisk's earlier wholesale cuts of roughly 10 to 44 percent before Mounjaro's Korean launch. Analysts note Eppe's trial results cannot be directly compared with rivals' studies, and its market share will depend on final pricing and physician and patient uptake.

Korea's first homegrown GLP-1 raises competitive pricing questions against Mounjaro and Wegovy.

Korea's first homegrown GLP-1 raises competitive pricing questions against Mounjaro and Wegovy. — impact context not separately stored; see What changed.